文献速递造血干细胞移植与细胞治疗

耐受性抗IL-2单抗预防移植物抗宿主病同时保留强移植物抗白血病活性

Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
PubMed 文献 · Blood · 2021-01-01

在小鼠异基因造血细胞移植模型中,早期给予耐受性抗IL-2单抗JES6可显著减轻急性GVHD,同时保留比他克莫司更强的GVL活性。机制涉及下调IL-2-Stat5通路、减少GM-CSF产生、增强PD-1/PD-L1相互作用及Tr1细胞扩增,并在淋巴组织中保留CD8+ T记忆祖细胞。

要点

  • 早期使用JES6可减轻急性GVHD且保留强GVL活性。
  • JES6的GVL活性显著强于他克莫司处理。
  • 机制涉及PD-1/PD-L1轴及Tr1细胞扩增。

核心结论

  • 早期给予耐受性抗IL-2单抗JES6可预防急性GVHD并保留强GVL活性。

研究设计与样本

  • 小鼠异基因造血细胞移植模型,比较JES6与他克莫司对GVHD和GVL的影响。

主要发现

  • JES6显著减轻急性GVHD,GVL活性明显强于他克莫司。
  • JES6下调IL-2-Stat5通路活化并减少GM-CSF产生。
  • GVHD靶组织中PD-1与PD-L1相互作用增强,抑制mTOR通路并增加Eomes和Blimp-1表达。
  • JES6促进T细胞无反应/耗竭、扩增Foxp3-IL-10+ Tr1细胞并清除GM-CSF+ Th1/Tc1细胞。
  • 受体淋巴组织中供者PD-1+TCF-1+Ly108+CD8+ T记忆祖细胞得以保留。

临床怎么用

  • 异基因造血细胞移植后早期使用耐受性抗IL-2单抗可能成为分离GVHD与GVL的新策略。

局限性

  • 证据来自小鼠模型,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Donor T cells mediate both graft-versus-leukemia (GVL) activity and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Development of methods that preserve GVL activity while preventing GVHD remains a long-sought goal. Tolerogenic anti-interleukin-2 (IL-2) monoclonal antibody (JES6-1) forms anti-IL-2/IL-2 complexes that block IL-2 binding to IL-2Rβ and IL-2Rγ on conventional T cells that have low expression of IL-2Rα. Here, we show that administration of JES6 early after allo-HCT in mice markedly attenuates acute GVHD while preserving GVL activity that is dramatically stronger than observed with tacrolimus (TAC) treatment. The anti-IL-2 treatment downregulated activation of the IL-2-Stat5 pathway and reduced production of granulocyte-macrophage colony-stimulating factor (GM-CSF). In GVHD target tissues, enhanced T-cell programmed cell death protein 1 (PD-1) interaction with tissue-programmed cell death-ligand 1 (PD-L1) led to reduced activation of protein kinase-mammalian target of rapamycin pathway and increased expression of eomesodermin and B-lymphocyte-induced maturation protein-1, increased T-cell anergy/exhaustion, expansion of Foxp3-IL-10-producing type 1 regulatory (Tr1) cells, and depletion of GM-CSF-producing T helper type 1 (Th1)/cytotoxic T cell type 1 (Tc1) cells. In recipient lymphoid tissues, lack of donor T-cell PD-1 interaction with tissue PD-L1 preserved donor PD-1+TCF-1+Ly108+CD8+ T memory progenitors and functional effectors that have strong GVL activity. Anti-IL-2 and TAC treatments have qualitatively distinct effects on donor T cells in the lymphoid tissues, and CD8+ T memory progenitor cells are enriched with anti-IL-2 treatment compared with TAC treatment. We conclude that administration of tolerogenic anti-IL-2 monoclonal antibody early after allo-HCT represents a novel approach for preventing acute GVHD while preserving GVL activity.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Song Q, Wang X, Wu X, et al. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. Blood. 2021. PMID: 33511398. doi:10.1182/blood.2020006345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。